Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 14/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.41 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23927070 | 0.80 | HSPB1 (0.50) | ARALDH1A1SLC22A12PLA2G7 | |
| SCHEMBL18519395 | 0.77 | KDM4E (0.52) | ARKDM4EUSP2ALDH1A1 | |
| SCHEMBL31125111 | 0.77 | KDM4E (0.52) | ARKDM4EUSP2ALDH1A1 | |
| SCHEMBL22069588 | 0.75 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL29437997 | 0.74 | KDM4E (0.50) | ARKDM4EUSP2ALDH1A1SLC22A12 | |
| SCHEMBL23927044 | 0.74 | KDM4E (0.50) | ARKDM4EUSP2ALDH1A1SLC22A12 | |
| SCHEMBL11755141 | 0.74 | AR (0.46) | ARKDM4ESLC22A12 | |
| SCHEMBL28697603 | 0.72 | SLC22A12 (0.51) | ARKDM4EUSP2ALDH1A1SLC22A12 | |
| SCHEMBL1642817 | 0.72 | ALOX5AP (0.52) | ARKDM4EUSP2ALDH1A1SLC22A12 | |
| SCHEMBL2881516 | 0.72 | SLC22A12 (0.51) | ARKDM4EUSP2ALDH1A1SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230124087-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230124087-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-4139306-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | F. Hoffmann-La Roche AG (CH) | 2023-03-01 | — | — | EP | disclosed |
| CN-115380032-A | KV3 enhancers for the treatment of cognitive disorders | 豪夫迈·罗氏有限公司 | 2022-11-22 | — | — | CN | disclosed |
| WO-2021214090-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021214090-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-10-28 | — | — | WO | disclosed |
| EP-3901152-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| EP-3901152-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230124087-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | KCNN3, KCNA4, KCNA3 | AR 3004/4885KDM4E 200/4885USP2 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.